|Bid||1.110 x 900|
|Ask||1.120 x 1100|
|Day's Range||1.1100 - 1.2100|
|52 Week Range||0.9900 - 15.3290|
|Beta (3Y Monthly)||-1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.86|
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.
ALPHARETTA, Ga., Jan. 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location - anterior, intermediate, posterior or pan. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. One was that the company's COO and CFO, Mark Hirschhorn had sold over $700,000 worth of shares last Friday, which amounted to over 81% of his stake in the company.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results will be released at approximately 7:00 a.m. ET on Thursday, November 8, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review.
It’s Monday and oil futures are relatively stable despite the news that the U.S. is beginning to impose sanctions on Iran again. Among the stocks making substantial waves today include Inuvo Inc. (NYSE:INUV), Clearside Biomedical Inc. (NASDAQ:CLSD), Sysco Corporation (NYSE:SYY), STMicroelectronics N.V. (NYSE:STM), and Cirrus Logic Inc. (NASDAQ:CRUS). Let’s dig deeper into why each stock moved. In the financial world […]
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data -.
ALPHARETTA, Ga., Oct. 29, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A. to the position of Chief Medical Officer. Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. Today, he remains a volunteer Clinical Professor of Ophthalmology at the university and also serves on the Board of Directors of Midwest Eye Institute. Dr. Ciulla is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology.
Clearside Biomedical Inc (NASDAQ:CLSD) is a small-cap stock with a market capitalization of US$210.7m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...